Co-Diagnostics Designs Test to Detect Mutations for New Coronavirus Strain Using CoPrimerâ„¢ Platform
Co-Diagnostics Designs Test to Detect Mutations for New Coronavirus Strain Using CoPrimerâ„¢ Platform Proprietary Company design process facilitates rapid response in detecting mutation of a new coronavirus strain circulating in the UK |
[22-December-2020] |
SALT LAKE CITY, Dec. 22, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed principal design work for a PCR test that would allow researchers to identify certain mutations in a newly detected variant of SARS-CoV-2 known as VUI 202012/01. The new coronavirus strain comprises several mutations and may be more contagious than its predecessors. London and the southeast of Great Britain began Sunday morning at Level 4, which requires the effective closure of the affected areas, and further limits contact with others. Travel restrictions have also been put in place by countries concerned about exposure to the new strain of the virus. Dwight Egan, CEO of Co-Diagnostics, commented "One of the most important advantages of our CoPrimerâ„¢ platform is its ability to reliably and accurately differentiate between similar genetic sequences, in order to reduce the likelihood of a false positive diagnosis. The multiplexing capabilities of our CoPrimer platform go hand-in-glove with the technology's applications in detecting small genetic variations in a given gene. As we have demonstrated earlier on during this pandemic, our technology also facilitates rapid test development that we believe could help get testing solutions on the ground quickly as impactful mutations are identified." Co-Diagnostics also confirmed that the genetic mutations in the new variant are not believed to interfere with the performance of the Company's existing line of COVID-19 diagnostics, and that any new test developed for this mutation would be a separate product, distinct from the Company's other tests. About Co-Diagnostics, Inc.: Forward-Looking Statements: View original content to download multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-designs-test-to-detect-mutations-for-new-coronavirus-strain-using-coprimer-platform-301197387.html SOURCE Co-Diagnostics | ||
Company Codes: NASDAQ-SMALL:CODX |
© 2020 PR Newswire. All Rights Reserved.